Decoding Tumor Heterogeneity through Multi Omics: Insights into Cancer Evolution, Microenvironment and Therapy Resistance
Résumé
Background: The existence of genetically, epigenetically, and phenotypically distinct cell populations inside and between tumors is known as tumor heterogeneity, and it is one of the main barriers to effective cancer treatment. This intricacy affects the likelihood of metastasis, therapeutic resistance, and disease recurrence, rendering single-omics methods and conventional diagnostics inadequate for whole-tumor profiling. As a result, multi-omics methods, which incorporate data from multiple biological layers, such as transcriptomics, proteomics, metabolomics, genomes, and epigenomics, have emerged as powerful tools for thoroughly examining intra- and inter-tumoral complexity. Methods: A comprehensive literature synthesis was conducted, emphasizing high-impact studies that illustrate technological innovation and translational impact in multi-omics applications. Key case studies in glioblastoma, non-small cell lung cancer, and breast cancer are highlighted to demonstrate real-world clinical relevance. Aims and Objectives: This paper explores the ways in which integrated multi-omics has transformed our understanding of clonal dynamics, tumor growth, and resistance mechanisms while charting a path toward precision oncology. Key Insights: The latest methods, such as single-cell multi-omics, spatial transcriptomics, and proteogenomics, were examined, along with computational frameworks including network-based models, probabilistic inference algorithms, and AI-driven tools that make it easier to integrate high-dimensional data. Along with discussing new technologies like in vivo biosensors, organoid-based modeling, and point-of-care omics, the function of the tumor microenvironment, lineage tracing, and liquid biopsies in monitoring the real-time progression of tumors was also discussed. Translational hurdles, including cost, complexity, and ethical issues were addressed while highlighting the importance of equity and worldwide access. Conclusion: Multi-omics has great promise for truly personalized oncology by providing the integrated insights required for dynamic monitoring, predictive diagnosis, and tailored therapy design in future cancer care.